New directions for drug discovery in psychiatric disease by Speeding, Michael et al.
he therapies for psychiatric disease have not
been revolutionized in the last 10 years and no major
new anxiolytics or antidepressants have appeared
(although some interesting compounds are in develop-
ment).The second generation of antipsychotics certainly
allows better therapy, particularly in terms of cognitive
aspects, but trade off improved tolerance, in terms of
extrapyramidal side effects, for metabolic side effects
(particularly weight gain) and, in some instances, car-
diovascular issues.
Although there have never been as many recognized
potential targets for drug therapy in psychiatric disease as
at present,there has been no major progress in terms of
marketed agents revolutionizing therapy. The partial
cloning of the human genome now allows us to define the
total number of receptors in the human genome (for
example,about 48 nuclear receptors,about 750 receptors
coupled to G proteins). This is a definitive statement
defining the future,and perhaps eventually the limits,of
drug discovery.One of us (M.Spedding) is chairman of
the Nomenclature Committee for the International
Union of Pharmacology (NC-IUPHAR),which has the
mission of classifying these receptors.The sequences of
the receptors coupled to G proteins (GPCRs) have now
been defined, and the olfactory receptors and pseudo-
genes separated, leaving several hundred known or
orphan receptors that may be drug targets. However,
screening for agonists and antagonists,and then proceed-
ing to clinical trials to test whether a certain hypothesis
works,is one of the most expensive experiments known
to man! Furthermore,the main reason for the failure of
new drugs when they get into clinical trials is not phar-
macokinetics or toxic side effects, but lack of efficacy
(Figure 1).
This lack of efficacy means that either the original
hypothesis of why the drug should work in man was
wrong or—and this is more likely—that the tests per-
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T
Although many new potential drug targets have been dis-
covered subsequent to the cloning of the human genome
and the discovery of most of the relevant receptors, the
role of these receptors in psychiatric disease is still not
clear. We argue that research into the disease process
leading to new animal models that can be transposed to
man is critical to drug discovery, and present an example
of an animal model for schizophrenia using electroen-
cephalography.
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formed in animals where the drug was active did not
measure the same parameters as the tests in phase 1 or 2
clinical trials (which,in turn,may not reflect the disease
situation).As there are now hundreds of potential targets
from the human genome, and most compounds going
into man appear not to be effective,what can be done? 
The response by much of the pharmaceutical industry is
to push up screening of new targets by high-throughput
testing of chemical libraries on new receptors (or other
potential targets), eliminating targets that do not yield
active results in disease models (frequently based on
transgenic animals), and then taking promising com-
pounds into the clinic for abbreviated “proof of concept”
testing in man.However,it is not always possible to have
proof of concept testing that reflects the situation in
diverse patient populations.
An alternative approach is to benefit from the break-
throughs made in basic research in brain function over
the last few years to study the pathology in man, and
then construct new animal models which better mimic
the disease state.It may then be possible to have animal
testing and early clinical testing performed in very sim-
ilar conditions, which will eliminate the risk of not test-
ing for the same effect.
Drug screening in vivo
If animal models are new,and reflect the disease state bet-
ter, then they may allow different compounds to be
selected if final compound selection is performed in the
disease model.Thus very different compounds will be cho-
sen for drug development.The disease state may change
the kinetics of receptor interactions or the multiple states
of a receptor,meaning that screening in normal conditions
may not be appropriate.From thermodynamics,changing
affinity by 100- to 1000-fold (ie, a enormous change in
structure–activity) may reflect a change in only one hydro-
gen bond between ligand and receptor,which is very dif-
ficult to predict on a molecular level.Thus,it is likely that
conformational modifications in a disease state—if the tar-
get is really a causative agent in the disease process—
would involve changes of such a magnitude. Indeed,
switching the conformation of a receptor between agonist
or antagonist states can change the affinity by more than
a 1000-fold, entirely changing the structure–activity,
because of changes in different binding pockets.
1-3Thus,dif-
ferences between receptor “states”can be more important
than differences between types of receptor.
2
It is thus clear then that screening in appropriate disease
models, rather than on putative receptor targets under
normal conditions, would lead to drugs better targeted
toward the pathological events, and thus toward better
treatment of the patient.
It is also important to ensure that the same measures can
be made in animals as in clinical testing.This may be eas-
ily accessible in the cardiovascular system,but studies in
the central nervous system (CNS) may require more
indirect comparisons. However, some end points are
amenable. We have studied electroencephalographic
(EEG) techniques and extensively characterized means
of transferring preclinical effects in conscious animals
toward the same effects in man, as clinical EEG is a
powerful means of defining the effects of drugs.
Which models may be used for 
schizophrenia?
Abnormalities in the neural circuits in the prefrontal
cortex, which are involved in working memory, are the
basis of the model of schizophrenia proposed by
Goldman-Rakic,
4,5 and have been seen in imaging stud-
ies.
6A robust reduction (>3.5 million) in the number of
thalamic neurones innervating frontal regions has been
Figure 1. Reasons for stopping clinical development of 121 compounds
from 7 British companies (B. Cox, personal communication).
Reproduced from reference 21: Sebban C, Tesolin-Decros S, Ciprian-Ollivier J,
Perret L, Spedding M. Effects of phencyclidine (PCP) and MK 801 on the EEGq
in the prefrontal cortex of the conscious rats; antagonism by clozapine, and
antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. Br J Pharmacol.
2002;135:65-78. Copyright © 2002, Nature Publishing Group.
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50reported in subjects with schizophrenia.
7 Thus, the pre-
frontal cortex is a key area and the hippocampus is also
important because the neurodevelopment model of
schizophrenia indicates changes in its development.
8,9
Phencyclidine (PCP) is an N-methyl-D-aspartate
(NMDA) antagonist that induces hallucinations in man.
PCP and the structurally related molecule ketamine
have been shown to exacerbate existing psychotic dis-
orders in schizophrenics and to reactivate symptoms in
remittance.
10-17 Use of PCP in animals and of ketamine
in man has been claimed to be the most valid model for
schizophrenia today.
18
Drug-induced changes in EEG
The effects of PCP were not well characterized in the
EEG of animals, and so we set up an animal model of
the EEG effects of PCP.We had previously characterized
more than 50 drug-induced changes in a model of EEG
of prefrontal cortex, using the somatosensori-motor
region as a control for effects on motor functions.
19,20
Chronically implanted EEG leads in the prefrontal cor-
tex of conscious rats are used to obtain “fingerprints”of
drug profiles over the range of 1 to 30 Hz
19,20 by sub-
tracting the control EEG from the EEG spectrum in the
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Figure 2. Dose–response effects of subcutaneous phencyclidine (PCP) 1 mg.kg
-1 on electroencephalographic (EEG) spectral power in the prefrontal cor-
tex and sensorimotor cortex in conscious rats. The abscissa represents the EEG spectral component between 1 and 30 Hz. The horizontal line
at zero indicates no change. The ordinate indicates the percentage change in the EEG power spectrum produced by drug administration, as
a percentage of the EEG spectrum obtained with vehicle administration 24 h earlier. The increases in EEG power may be taken as a syn-
chronization of EEG at the particular frequency and a decrease in power as a desynchronization. Because of local factors (electrode place-
ment) synchronization of the EEG change yields larger percentage changes than desynchronization. Vertical bars for each point show 95%
confidence intervals (n=6). Note the massive synchronization at low frequencies and the desychronization at higher frequencies.
Reproduced from reference 21: Sebban C, Tesolin-Decros S, Ciprian-Ollivier J, Perret L, Spedding M. Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cor-
tex of the conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. Br J Pharmacol. 2002;135:65-78. Copyright © 2002, Nature
Publishing Group.
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presence of the test drug 24 hours later.We reported that
activation of noradrenergic and dopaminergic receptors
causes a decrease in EEG power (desynchronization),
whereas inhibition of these two systems increases EEG
power (synchronization).
19,20 Decreases in EEG power in
this model are induced by agents which increase vigi-
lance,such as modafinil.
19,20 Interestingly,nearly all the
antipsychotic agents that we tested (clozapine,haloperi-
dol, and risperidone) increased theta/alpha1 power
(peaks between 7 and 8 Hz),
19-21 indicating an impact on
cortical processes in the prefrontal cortex, as theta
rhythm is involved in memory processes and neuronal
plasticity.We found that antipsychotic agents (haloperi-
done, chlorpromazine, risperidone, clozapine, and
olanzepine) increased theta frequencies (about 8 Hz) in
the rat prefrontal cortex.Theta rhythm is 4 to 7 Hz in
man and 3 to 12 in rats (usually 7±2 Hz),and is increased
by movement, implying a role in motor function: the
faster a rat runs, the faster the theta rhythm. Theta
appears during rapid eye movement (REM) sleep.
Theta rhythm is used to create a unit of cell assemblies,
across the brain, in phase, working on a common prob-
lem.Thus,theta also has the capacity to separate assem-
blies that are working on different problems.Thus, the
fact that antipsychotic agents increase the probability of
theta rhythm in the prefrontal cortex indicates direct
effects in cognitive processes.
In contrast, while studying the effects of the propsy-
chotic NMDA antagonist PCP,to our surprise,we found
massive increases in EEG spectral power at low fre-
quencies (<4 Hz) and a powerful reduction in power
(desynchronization) at 6 to 30 Hz.The model was sim-
ple: implantation of transcortical electrodes in the pre-
frontal and sensorimotor cortices with analysis of EEG
power spectra between 1 and 30 Hz over 3 hours.The
effects of the vehicle, administered on the first day, was
Figure 3. Dose–response effects of subcutaneous clozapine (0.2 mg.kg
-1) expressed as percentage change of electroencephalographic (EEG) spectral
power in the prefrontal cortex and sensorimotor cortex of conscious rats at each frequency between 1 and 30 Hz. Vertical bars represent
95% confidence intervals (n=6).
Reproduced from reference 21: Sebban C, Tesolin-Decros S, Ciprian-Ollivier J, Perret L, Spedding M. Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cor-
tex of the conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. Br J Pharmacol. 2002;135:65-78. Copyright © 2002, Nature
Publishing Group.
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the second day,allowing an EEG power spectrum of the
effects of the drugs. The results were published by
Sebban et al
21 in 2001,and are summarized here:
•The EEG effects of the propsychotic agent PCP
showed that PCP (0.1-3 mg.kg
-1,subcutaneous) (Figure
2) caused a marked dose-dependent increase in EEG
power in the frontal cortex at 1 to 3 Hz,with decreases
in power at higher frequencies (9-30 Hz).MK801 (0.05-
0.1 mg.kg
-1,intraperitoneal [IP]) caused similar effects,
but with lesser changes in power.
• In contrast, the noncompetitive AMPA (amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid) antago-
nists GYKI 52466 and GYKI 53655 increased EEG
power over the whole power spectrum (1-10 mg.kg
-1,IP).
• Clozapine,an atypical antipsychotic agent (0.2 mg.kg
-1,
subcutaneous) synchronized the EEG (peak 8 Hz)
(Figure 3).The 5-HT2A antagonist M100907 specifically
increased EEG power at 2 to 3 Hz at low doses (10 and
50 µg.kg
-1,subcutaneous),whereas at higher doses (0.1
mg.kg
-1, subcutaneous) the profile resembled that of
clozapine.
• Clozapine (0.2 mg.kg
-1,subcutaneous),GYKI 53655 (5
mg.kg
-1, IP), prazosin (0.05 and 0.1 mg.kg
-1, IP), and
M100907 (0.01 and 0.05 mg.kg
-1,subcutaneous) antago-
nized the decrease in power between 5 and 30 Hz caused
by PCP (1 mg.kg
-1,subcutaneous),but not the increase
in power at 1 to 3 Hz in prefrontal cortex (Figure 4).
Conclusion
Thus,clozapine,supposedly the best antipsychotic agent
available, apart from its limiting side effects, clearly
increased theta rhythm in prefrontal cortex,indicating ben-
eficial effects on cognition.Clozapine also partially antag-
onized the effects of PCP on EEG, but only the desyn-
chronization.These results clearly show that the effects of
PCP on EEG can be used a model for schizophrenia,
which may be transposable to man.The profiles of com-
pounds screened for activity in this model are allowing new
therapies for schizophrenia to be developed,particularly if
all the effects of PCP may be antagonized. ❏
We thank Isabelle Neau for help with preparation of the manuscript.
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Figure 4. Coadministration of subcutaneous phencyclidine (PCP) (1 mg.kg
-1) and clozapine (0.2 mg.kg
-1), expressed as percentage change of elec-
troencephalographic (EEG) spectral power in the prefrontal cortex and sensorimotor cortex of conscious rats at each frequency between 1
and 30 Hz. Vertical bars represent 95% confidence intervals (n=6).
Reproduced from reference 21: Sebban C, Tesolin-Decros S, Ciprian-Ollivier J, Perret L, Spedding M. Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cor-
tex of the conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. Br J Pharmacol. 2002;135:65-78. Copyright © 2002, Nature
Publishing Group.
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Nuevas tendencias para el descubrimiento
de fármacos en la enfermedad psiquiátrica
El papel de los receptores en la enfermedad psi-
quiátrica aun no está aclarado, aunque reciente-
mente se han descubierto nuevas posibilidades en el
uso de los fármacos como consecuencia de la clona-
ción del genoma humano y del descubrimiento de
la mayoría de los receptores importantes. Nosotros
argumentamos que la investigación en los procesos
patológicos que conducen a nuevos modelos ani-
males que se pueden traspasar al hombre es crítica
en el descubrimiento de fármacos y presentamos un
ejemplo de un modelo animal para la esquizofrenia
utilizando la electroencefalografía.
Les voies de l'innovation thérapeutique en
psychiatrie
Le clonage du génome humain a permis de décou-
vrir de nombreuses cibles potentielles nouvelles pour
les médicaments et de mettre en évidence la plupart
des récepteurs qui leur sont associés. Cependant, le
rôle de ces derniers dans la maladie psychiatrique
reste obscur. Il est clair, en ce qui nous concerne, que
la recherche sur les processus morbides conduisant à
de nouveaux modèles animaux transposables à
l’homme est essentielle pour la découverte de médi-
caments. À ce titre, nous proposons un exemple de
modèle animal pour la schizophrénie utilisant l’élec-
troencéphalographie.